These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 34089308)

  • 21. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week.
    Gonzalez-Lopez E; McPhail ED; Salas-Anton C; Dominguez F; Gertz MA; Dispenzieri A; Dasari S; Milani P; Verga L; Grogan M; Palladini G; Garcia-Pavia P
    J Am Coll Cardiol; 2024 Mar; 83(11):1085-1099. PubMed ID: 38479957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
    Gopal DM; Ruberg FL; Siddiqi OK
    Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac amyloidosis-A review of current literature for the practicing physician.
    Ash S; Shorer E; Ramgobin D; Vo M; Gibbons J; Golamari R; Jain R; Jain R
    Clin Cardiol; 2021 Mar; 44(3):322-331. PubMed ID: 33595871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
    Warner AL
    Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A; Castiglione V; Rapezzi C; Franzini M; Panichella G; Vergaro G; Gillmore J; Fontana M; Passino C; Emdin M
    Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
    Arbustini E; Gavazzi A; Merlini G
    Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
    Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
    Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
    González-López E; López-Sainz Á; Garcia-Pavia P
    Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy.
    Alwan L; Benz DC; Cuddy SAM; Dobner S; Shiri I; Caobelli F; Bernhard B; Stämpfli SF; Eberli F; Reyes M; Kwong RY; Falk RH; Dorbala S; Gräni C
    JACC Cardiovasc Imaging; 2024 Feb; 17(2):195-211. PubMed ID: 38099914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.
    Hänselmann A; Berliner D; Bauersachs J; Bavendiek U
    Herz; 2022 Aug; 47(4):324-331. PubMed ID: 35674775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
    Nuvolone M; Girelli M; Merlini G
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
    Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
    Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
    Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
    Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.